Recent News for PAA - PharmAust Limited

Date	Title
Feb 28	PharmAust advances monepantel for motor neurone disease towards FDA approval
Feb 28	PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
Feb 14	PharmAust (ASX:PAA) delivers shareholders incredible 42% CAGR over 5 years, surging 11% in the last week alone